Log in to save to my catalogue

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relaps...

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relaps...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930695

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma

About this item

Full title

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Publisher

Switzerland: MDPI AG

Journal title

Cancers, 2024-02, Vol.16 (5), p.1023

Language

English

Formats

Publication information

Publisher

Switzerland: MDPI AG

More information

Scope and Contents

Contents

Multi-agent regimens incorporating immunomodulatory (IMiD
) agents such as thalidomide, lenalidomide, and pomalidomide have become the preferred standard of care for the treatment of patients with multiple myeloma (MM), resulting in improved survival outcomes. Currently, there are three IMiD agents approved for the treatment of MM: thalidomide,...

Alternative Titles

Full title

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930695

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930695

Other Identifiers

ISSN

2072-6694

E-ISSN

2072-6694

DOI

10.3390/cancers16051023

How to access this item